13,000 Shares in Cybin Inc. (NYSE:CYBN) Bought by Cowa LLC

Cowa LLC acquired a new position in shares of Cybin Inc. (NYSE:CYBN) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 13,000 shares of the company’s stock, valued at approximately $115,000. Cowa LLC owned about 0.06% of Cybin as of its most recent filing with the SEC.

Separately, Global Retirement Partners LLC purchased a new position in Cybin during the 4th quarter worth $46,000. 17.94% of the stock is owned by hedge funds and other institutional investors.

Cybin Price Performance

Shares of CYBN opened at $9.09 on Friday. The company has a 50-day moving average of $9.50. The stock has a market cap of $192.07 million, a P/E ratio of -2.07 and a beta of 0.46. Cybin Inc. has a 52-week low of $6.50 and a 52-week high of $19.85.

Analyst Ratings Changes

CYBN has been the subject of a number of analyst reports. HC Wainwright cut their price objective on shares of Cybin from $190.00 to $150.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Canaccord Genuity Group cut their price target on shares of Cybin from $86.00 to $73.00 and set a “buy” rating for the company in a report on Wednesday, February 12th.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.